232 related articles for article (PubMed ID: 29388415)
1. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.
Albisinni S; Aoun F; Marcelis Q; Jungels C; Al-Hajj Obeid W; Zanaty M; Tubaro A; Roumeguere T; De Nunzio C
Minerva Urol Nefrol; 2018 Aug; 70(4):347-360. PubMed ID: 29388415
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
[TBL] [Abstract][Full Text] [Related]
3. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
4. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature.
Manfredi C; Fernández-Pascual E; Arcaniolo D; Emberton M; Sanchez-Salas R; Artigas Guix C; Bianco F; Cathcart P; Murphy DG; Couñago F; Martínez-Ballesteros C; Verze P; Martínez-Salamanca JI
Eur Urol Focus; 2022 Jul; 8(4):942-957. PubMed ID: 34538633
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
7. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
8. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
[TBL] [Abstract][Full Text] [Related]
9. Prospective head-to-head comparison of
Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
[TBL] [Abstract][Full Text] [Related]
10. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
11. Rationale for Modernising Imaging in Advanced Prostate Cancer.
Padhani AR; Lecouvet FE; Tunariu N; Koh DM; De Keyzer F; Collins DJ; Sala E; Fanti S; Vargas HA; Petralia G; Schlemmer HP; Tombal B; de Bono J
Eur Urol Focus; 2017 Apr; 3(2-3):223-239. PubMed ID: 28753774
[TBL] [Abstract][Full Text] [Related]
12. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
13. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of imaging-guided metastasis-directed therapy for oligorecurrent prostate cancer: revolution or devolution?
Albisinni S; Van Damme J; Aoun F; Bou Kheir G; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2020 Jun; 72(3):279-291. PubMed ID: 32083417
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Gauthé M; Zarca K; Aveline C; Lecouvet F; Balogova S; Cussenot O; Talbot JN; Durand-Zaleski I
BMC Med Imaging; 2020 Mar; 20(1):25. PubMed ID: 32122345
[TBL] [Abstract][Full Text] [Related]
17. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
18. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
19. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of
Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
